GLP-1s are changing the way we think about diabetes and obesity treatment, dominating headlines and raising questions about their long-term effects.
A new study explores whether these drugs may offer an unexpected benefit — protection against eye disease. Join the study’s co-author, Benjamin K. Young, M.D., M.S., for a deep dive into the surprising link between GLP-1 use and age-related macular degeneration.
What we’ll cover:
- The basics of GLP-1s and how they work
- How GLP-1s were discovered
- Emerging research on GLP-1 use and eye disease
About the presenter:
Benjamin K. Young, M.D., M.S., grew up in Omaha, Nebraska. He obtained a combined bachelor’s and master’s degree in chemistry at the University of Pennsylvania as a Roy Vagelos Molecular Life Sciences Scholar. Young completed medical school at Brown University, followed by an ophthalmology residency at Yale University, where he also served as chief resident. At the University of Michigan, he completed a fellowship in adult and pediatric vitreoretinal surgery, supported by a Heed Ophthalmic Fellowship. Young is now a clinician-scientist at OHSU Casey Eye Institute, focusing on quantitative techniques and complex image analysis for retinal disease.
